University Hospital Tuebingen
medizin.uni-tuebingen.deTotal trials
483
Active
96
Phase 3
30
Total enrollment
143,193
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 40 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dapagliflozin | — | — | — | — | — | 2 | |
| LECIG | — | — | — | — | — | 1 | |
| Best oral medication | — | — | — | — | — | 1 | |
| PfSPZ Challenge | — | — | — | — | 2 | ||
| Pyronaridine Tetraphosphate, Artesunate Drug Combination | — | — | — | — | — | 1 | |
| MVA ME-TRAP | — | — | — | — | — | 1 | |
| ChAd63 ME-TRAP | — | — | — | — | — | 1 | |
| Sodium chloride (NaCl) 0.9% | — | — | — | — | — | 1 | |
| Prasinezumab | — | — | — | — | — | 1 | |
| Sodium Chloride | — | — | — | — | — | 1 | |
| Peptide vaccine IPX | — | — | — | — | — | 1 | |
| Decitabine | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| CD318-CAR-T cells | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Tafasitamab | — | — | — | — | — | 1 | |
| CD45RA depleted donor lymphocyte | — | — | — | — | — | 1 | |
| Ketamine | — | — | — | — | — | 1 | |
| Belimumab 200 MG/ML [Benlysta] | — | — | — | — | — | 1 | |
| standard of care | — | — | — | — | — | 1 | |
| RIC regimen | — | — | — | — | — | 1 | |
| CC-1 | — | — | — | — | — | 1 | |
| Nivolumab [Opdivo] | — | — | — | — | — | 1 | |
| Vaccination of Fusion-VAC-XS15 | — | — | — | — | — | 1 | |
| Prime-2-CoV_Beta | — | — | — | — | — | 1 | |
| HY_133 | — | — | — | — | — | 1 | |
| CAR-T cells targeting CD19 and CD22 | — | — | — | — | — | 1 | |
| CC-1, PSMAxCD3 | — | — | — | — | — | 1 | |
| Vaccines, Peptide | — | — | — | — | — | 1 | |
| Fusion-VAC-XS15 | — | — | — | — | — | 1 | |
| NGS Diagnostic | — | — | — | — | — | 2 | |
| SSRI treatment | — | — | — | — | — | 1 | |
| Molecular genetic diagnostic | — | — | — | — | — | 1 | |
| Retrospective data analysis | — | — | — | — | — | 1 | |
| Chemotherapy with 5-fluorouracil | — | — | — | — | — | 1 | |
| Consolidation chemotherapy with FOLFOX | — | — | — | — | — | 1 | |
| Biologic Agent | — | — | — | — | — | 1 | |
| WGS Diagnostic: Blood take for genetic diagnostic | — | — | — | — | — | 1 | |
| Next-Generation Sequencing | — | — | — | — | — | 1 | |
| Betamethason Sodium Phosphate | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2025-07-01
- 2025-10
- 2025-12
- 2025-12
- 2025-12-01
- 2025-12-31
- 2026-05
- 2026-05-02
- 2026-06-30
Top conditions
- Obesity16
- Insulin Resistance13
- Rare Diseases9
- Major Depressive Disorder8
- Depression8
- COVID-197
- Diabetes Mellitus, Type 26
- Malignant Melanoma6
Frequently asked questions about University Hospital Tuebingen
- How many clinical trials does University Hospital Tuebingen have on ClinicalTrials.gov?
- University Hospital Tuebingen is listed as the lead sponsor on 483 clinical trials in ClinicalTrials.gov, 96 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Tuebingen's trials are in Phase 3?
- 30 of University Hospital Tuebingen's trials are in Phase 3, spread across 40 active drug programs.
- What therapeutic areas does University Hospital Tuebingen focus on?
- University Hospital Tuebingen's most-studied conditions on ClinicalTrials.gov are Obesity, Insulin Resistance, Rare Diseases, Major Depressive Disorder, Depression.
- When are University Hospital Tuebingen's next clinical trial readouts?
- University Hospital Tuebingen has 10 upcoming primary-completion readouts tracked here; the soonest is “Stress and Fetal Brain Development”, expected around 2024-12-31.